Sunny Pharmtech Balance Sheet Health
Financial Health criteria checks 5/6
Sunny Pharmtech has a total shareholder equity of NT$1.2B and total debt of NT$345.0M, which brings its debt-to-equity ratio to 29.7%. Its total assets and total liabilities are NT$1.7B and NT$503.0M respectively.
Key information
29.7%
Debt to equity ratio
NT$345.00m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$221.23m |
| Equity | NT$1.16b |
| Total liabilities | NT$503.02m |
| Total assets | NT$1.67b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6676's short term assets (NT$434.9M) exceed its short term liabilities (NT$134.4M).
Long Term Liabilities: 6676's short term assets (NT$434.9M) exceed its long term liabilities (NT$368.6M).
Debt to Equity History and Analysis
Debt Level: 6676's net debt to equity ratio (10.6%) is considered satisfactory.
Reducing Debt: 6676's debt to equity ratio has reduced from 30% to 29.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6676 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 6676 has less than a year of cash runway if free cash flow continues to grow at historical rates of 25.1% each year.